Vaccines and monoclonal antibodies

Seminars in Oncology

Volumn 32, Issue SUPPL. 9, 2005, Pages 82-86

  Michaeli, Dov ^a  

^a Aphton Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CEA TRICOM; CETUXIMAB; G17DT; IMMUNOGLOBULIN; IRINOTECAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOISOTOPE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL MEDIATED CYTOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

EID: 30544455293     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.06.013     Document Type: Conference Paper

References (26)

1. IARC globoscan. Available at: http://www-dep.iarc.fr/
2. A. Jemal, T. Murray, A. Samuels Cancer Statistics, 2005 CA Cancer J Clin 55 2005 10 30
3. S. Brandlein, T. Pohle, C. Vollmers CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1 Oncol Rep 11 2004 777 784
4. S.J. Gong, C.J. Jin, S.Y. Rha Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines Cancer Lett 214 2004 215 224
5. Y. Hinoda, S. Sasaki, T. Ishida Monoclonal antibodies as effective therapeutic agents for solid tumors Cancer Sci 95 2004 621 625
6. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689 708
7. K. Shimizu, H. Kubo, K. Yamaguchi Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer Cancer Sci 95 2004 328 333
8. G.N. Hortobagyi, E.A. Perez Integration of trastuzumab into adjuvant systemic therapy of breast cancer Ongoing and planned clinical trials Semin Oncol 28 suppl 16 2001 41 46
9. L. Norton Evolving concepts in the systemic drug therapy of breast cancer Semin Oncol 24 suppl 10 1997 S10-3 S10-10
10. Y. Wang, Q. Gu, B. Liu Perspectives of SEREX-defined antigens in diagnosis and immunotherapy for gastric cancer Cancer Biol Ther 3 2004 806 811
11. Y. Oki, A. Younes Heat shock protein-based cancer vaccines Expert Rev Vaccines 3 2004 403 411
12. Y. Ueda, Y. Sonoda, H. Fujiki Mobilization of peripheral blood stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in advanced gastric cancer Oncol Rep 12 2004 323 332
13. P. Sutton, J. O'Rourke, J. Wilson Immunisation against helicobacter felis infection protects against the development of gastric MALT lymphoma Vaccine 22 2004 2541 2546
14. B.Y. Liu, X.H. Chen, Q.L. Gu Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer World J Gastroenterol 10 2004 630 633
15. E. Diaz-Rubio New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers Oncologist 9 2004 282 294
16. J.L. Marshall, J.L. Gulley, P.M. Arlen Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas J Clin Oncol 23 2005 720 731
17. C.M. Rocha Lima, R. Buck, K. Meyer A multicenter phase II study of irinotecan in combination with G17DT immunogen in subjects with metastatic colorectal adenocarcinoma (CRC) refractory to previous irinotecan-based chemotherapy. American Society of clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 suppl 2004 14S (abstr 3573)
18. J.R. Hecht, J.A. Ajani, D. Michaeli A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease Proc Am Soc Clin Oncol 22 2003 258 (abstr 1035)
19. A.D. Gilliam, E.G. Topuzov, A.M. Garin Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22 suppl 2004 14S (abstr 2511)
20. S.A. Watson, T.M. Morris, D.F. McWilliams Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence Br J Cancer 87 2002 567 573
21. S.A. Watson, A.D. Gilliam G17DT-A new weapon in the therapeutic armoury for gastrointestinal malignancy Expert Opin Biol Ther 1 2001 309 317
22. S.A. Watson, A.D. Gilliam, S. Grimeset Enhanced inhibition of pancreatic cancer by combination of the G17DT immunogen and gemcitabine Proc Am Soc Clin Oncol 21 2002 10a (abstr 37)
23. B. Levy, D. Panicalli, J. Marshall TRICOM Enhanced vaccines as anticancer therapy Expert Rev Vaccines 3 2004 397 402
24. E.K. Waller Cellular immunotherapy and cancer Semin Oncol 31 suppl 4 2004 87 90
25. Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done 2004 Humana Press Totowa, NY
26. Gastrin 17 vaccine - Aphton Anti-gastrin 17 immunogen, G17DT BioDrugs 17 2003 223 225